Abstract:Alzheimer’s disease (AD) is increasingly seen as a disease of synapses and diverse evidence has implicated the amyloid-β peptide (Aβ) in synapse damage. The molecular and cellular mechanism(s) by which Aβ and/or its precursor protein, the amyloid precursor protein (APP) can affect synapses remains unclear. Interestingly, early hyperexcitability has been described in human AD and mouse models of AD, which precedes later hypoactivity. Here we show that neurons in culture with either elevated levels of Aβ or with… Show more
“…Homeostatic scaling is necessary to maintain synaptic function within a physiological limit; thus, this scaling capability is of great interest in the context of neurodegenerative diseases such as AD (4). As AD progresses, accumulation of toxic amyloid oligomers in the hippocampus results in altered thresholds for LTP and LTD; synapse loss; and impairment of homeostatic scaling (6,29,30). As mentioned above, proSAAS functions as an amyloid anti-aggregant, both in vitro as well as in cell models of amyloid toxicity (12), and has been shown to bind amyloid (12,21).…”
Section: Discussionmentioning
confidence: 99%
“…Homeostatic mechanisms become defective in neurons expressing AD-related transgenes, as these neurons are unable to compensate for disruptions in network activity (6). The inability of neurons to constrain neuronal firing within a physiological limit leads to excessive strengthening or weakening of synapses, and eventually, neurological disorders (reviewed in (4)).…”
The accumulation of beta amyloid in Alzheimers disease greatly impacts neuronal health and synaptic function. To maintain network stability in the face of altered synaptic activity, neurons engage a feedback mechanism termed homeostatic scaling; however, this process is thought to be disrupted during disease progression. Previous proteomics studies have shown that one of the most highly regulated proteins in cell culture models of homeostatic scaling is the small secretory chaperone proSAAS. Our prior work has shown that proSAAS exhibits anti-aggregant behavior against alpha synuclein and beta amyloid fibrillation in vitro, and is upregulated in cell models of proteostatic stress. However, the specific role that this protein might play in homeostatic scaling, and its anti-aggregant role in Alzheimers progression, is not clear. To learn more about the role of proSAAS in maintaining hippocampal proteostasis, we compared its expression in a primary neuron model of homeostatic scaling to other synaptic components using Western blotting and qPCR, revealing that proSAAS protein responses to homeostatic up- and down-regulation were significantly higher than those of two other synaptic vesicle components, 7B2 and carboxypeptidase E. However, proSAAS mRNA expression was static, suggesting translational control (and/or reduced degradation). ProSAAS was readily released upon depolarization of differentiated hippocampal cultures, supporting its synaptic localization. Immunohistochemical analysis demonstrated abundant proSAAS within the mossy fiber layer of the hippocampus in both wild-type and 5xFAD mice; in the latter, proSAAS was also concentrated around amyloid plaques. Interestingly, overexpression of proSAAS in the CA1 region via stereotaxic injection of proSAAS-encoding AAV2/1 significantly decreased amyloid plaque burden in 5xFAD mice. We hypothesize that dynamic changes in proSAAS expression play a critical role in hippocampal proteostatic processes, both in the context of normal homeostatic plasticity and in the control of protein aggregation during Alzheimers disease progression.
“…Homeostatic scaling is necessary to maintain synaptic function within a physiological limit; thus, this scaling capability is of great interest in the context of neurodegenerative diseases such as AD (4). As AD progresses, accumulation of toxic amyloid oligomers in the hippocampus results in altered thresholds for LTP and LTD; synapse loss; and impairment of homeostatic scaling (6,29,30). As mentioned above, proSAAS functions as an amyloid anti-aggregant, both in vitro as well as in cell models of amyloid toxicity (12), and has been shown to bind amyloid (12,21).…”
Section: Discussionmentioning
confidence: 99%
“…Homeostatic mechanisms become defective in neurons expressing AD-related transgenes, as these neurons are unable to compensate for disruptions in network activity (6). The inability of neurons to constrain neuronal firing within a physiological limit leads to excessive strengthening or weakening of synapses, and eventually, neurological disorders (reviewed in (4)).…”
The accumulation of beta amyloid in Alzheimers disease greatly impacts neuronal health and synaptic function. To maintain network stability in the face of altered synaptic activity, neurons engage a feedback mechanism termed homeostatic scaling; however, this process is thought to be disrupted during disease progression. Previous proteomics studies have shown that one of the most highly regulated proteins in cell culture models of homeostatic scaling is the small secretory chaperone proSAAS. Our prior work has shown that proSAAS exhibits anti-aggregant behavior against alpha synuclein and beta amyloid fibrillation in vitro, and is upregulated in cell models of proteostatic stress. However, the specific role that this protein might play in homeostatic scaling, and its anti-aggregant role in Alzheimers progression, is not clear. To learn more about the role of proSAAS in maintaining hippocampal proteostasis, we compared its expression in a primary neuron model of homeostatic scaling to other synaptic components using Western blotting and qPCR, revealing that proSAAS protein responses to homeostatic up- and down-regulation were significantly higher than those of two other synaptic vesicle components, 7B2 and carboxypeptidase E. However, proSAAS mRNA expression was static, suggesting translational control (and/or reduced degradation). ProSAAS was readily released upon depolarization of differentiated hippocampal cultures, supporting its synaptic localization. Immunohistochemical analysis demonstrated abundant proSAAS within the mossy fiber layer of the hippocampus in both wild-type and 5xFAD mice; in the latter, proSAAS was also concentrated around amyloid plaques. Interestingly, overexpression of proSAAS in the CA1 region via stereotaxic injection of proSAAS-encoding AAV2/1 significantly decreased amyloid plaque burden in 5xFAD mice. We hypothesize that dynamic changes in proSAAS expression play a critical role in hippocampal proteostatic processes, both in the context of normal homeostatic plasticity and in the control of protein aggregation during Alzheimers disease progression.
“…Primary neuronal cultures were established following the ethical guidelines and approved by the Lund University Ethical committee (M46-16). Primary neurons were isolated from WT mouse embryos on embryonic day 16, as described before [ 40 ], 2000 cells per well were seeded on a 96-well plate pre-coated with poly-d-lysine (Sigma Aldrich) and then rinsed in autoclaved distilled water. Cell suspensions were plated in Dulbecco’s modified Eagle medium (DMEM) (Thermo Fisher Scientific) containing 10% FBS and 1% penicillin–streptomycin; after 3–5 h, media were exchanged for FBS-free complete Neurobasal medium (Gibco, Thermo Fisher Scientific).…”
Parkinson’s Disease (PD) is a neurodegenerative and progressive disorder characterised by intracytoplasmic inclusions called Lewy bodies (LB) and degeneration of dopaminergic neurons in the substantia nigra (SN). Aggregated α-synuclein (αSYN) is known to be the main component of the LB. It has also been reported to interact with several proteins and organelles. Galectin-3 (GAL3) is known to have a detrimental function in neurodegenerative diseases. It is a galactose-binding protein without known catalytic activity and is expressed mainly by activated microglial cells in the central nervous system (CNS). GAL3 has been previously found in the outer layer of the LB in post-mortem brains. However, the role of GAL3 in PD is yet to be elucidated. In post-mortem samples, we identified an association between GAL3 and LB in all the PD subjects studied. GAL3 was linked to less αSYN in the LB outer layer and other αSYN deposits, including pale bodies. GAL3 was also associated with disrupted lysosomes. In vitro studies demonstrate that exogenous recombinant Gal3 is internalised by neuronal cell lines and primary neurons where it interacts with endogenous αSyn fibrils. In addition, aggregation experiments show that Gal3 affects spatial propagation and the stability of pre-formed αSyn fibrils resulting in short, amorphous toxic strains. To further investigate these observations in vivo, we take advantage of WT and Gal3KO mice subjected to intranigral injection of adenovirus overexpressing human αSyn as a PD model. In line with our in vitro studies, under these conditions, genetic deletion of GAL3 leads to increased intracellular αSyn accumulation within dopaminergic neurons and remarkably preserved dopaminergic integrity and motor function. Overall, our data suggest a prominent role for GAL3 in the aggregation process of αSYN and LB formation, leading to the production of short species to the detriment of larger strains which triggers neuronal degeneration in a mouse model of PD.
“…Alterations in the AIS structure may be mediated by APP overexpression or soluble Aβ rather than, or in addition to, Aβ plaque toxicity. In cortical and hippocampal APP/PS1 primary neurons (where APP and soluble Aβ levels, but not plaques, is expected to be high), AISs were shorter than in wild-type (WT) mice and were not responsive to homeostatic changes in AIS length usually triggered by increasing (with bicuculline) or decreasing (with TTX) neuronal activity (Martinsson et al, 2022 ). Alternatively, applying soluble Aβ onto cultured hippocampal neurons impaired microtubule plus-end-binding protein 3 (EB3) stability at the AIS, thereby disturbing microtubule integrity and lengthening the AIS, and was accompanied by a depolarising shift in the AP voltage threshold (Tsushima et al, 2015 ).…”
Section: Disruption Of the Ais Structure In Amyloid Pathologymentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.